| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Continuous administration of the bone-derived osteocalcin (OC) resulted in increased GLP-1-producing cells in the pancreatic island in mice. Using acutely isolated mouse pancreatic islets and cultured α cells, we identified that OC directly acted on the receptor GPRC6A in pancreatic α cells to activate the cAMP pathway leading to the expression of the transcription factor Pax6. Then it was followed by promoting the expression of PC1/3 which converts proglucagon to GLP-1 instead of glucagon, and suppressing the expression of Pcsk1n that is an inhibitor of PC1/3 enzymatic activity. Thus, OC directly acts on the pancreatic α cells and induces switching its producing hormones.
|
